You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDorzolamide
Accession NumberDB00869  (APRD00577, DB04507)
TypeSmall Molecule
GroupsApproved
DescriptionDorzolamide is a carbonic anhydrase (CA) inhibitor. It is used in ophthalmic solutions (Trusopt) to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
Structure
Thumb
Synonyms
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4S,6S-Dorzolamide
Dorzolamid
Dorzolamida
Dorzolamide
Dorzolamidum
External Identifiers
  • L 671152
  • MK 507
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DorzolamideSolution2.0 %OphthalmicAlcon Canada IncNot applicableNot applicableCanada
Dorzolamide HydrochlorideSolution20 mg/mLOphthalmicPrasco Laboratories1994-12-09Not applicableUs
Dorzolamide Hydrochloride Ophthalmic SolutionSolution20 mgOphthalmicBausch & Lomb IncNot applicableNot applicableCanada
Jamp-dorzolamideSolution2 %OphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
Med-dorzolamideSolution2 %OphthalmicGeneric Medical Partners IncNot applicableNot applicableCanada
Sandoz DorzolamideSolution20 mgOphthalmicSandoz Canada Incorporated2010-10-25Not applicableCanada
TrusoptSolution2 %OphthalmicPurdue Pharma1996-12-31Not applicableCanada
TrusoptSolution20 mg/mLOphthalmicMerck Sharp & Dohme Corp.1994-12-09Not applicableUs
TrusoptSolution2 %OphthalmicPurdue Pharma2006-02-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dorzolamideSolution2 %OphthalmicApotex IncNot applicableNot applicableCanada
Dorzolamide HClSolution20 mg/mLOphthalmicActavis Pharma, Inc.2015-02-17Not applicableUs
Dorzolamide HClSolution / drops20 mg/mLOphthalmicA S Medication Solutions2009-06-25Not applicableUs
Dorzolamide HClSolution / drops22.3 mg/mLOphthalmicPhysicians Total Care, Inc.2012-02-21Not applicableUs
Dorzolamide HClSolution / drops20 mg/mLOphthalmicBausch & Lomb Incorporated2009-06-25Not applicableUs
Dorzolamide HydrochlorideSolution20 mg/mLOphthalmicTeva Pharmaceuticals Usa, Inc.2010-01-28Not applicableUs
Dorzolamide HydrochlorideSolution / drops20 mg/mLOphthalmicGolden State Medical Supply, Inc.2014-11-13Not applicableUs
Dorzolamide HydrochlorideSolution / drops20 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2008-10-28Not applicableUs
Dorzolamide HydrochlorideSolution / drops20 mg/mLOphthalmicSandoz Inc.2009-06-01Not applicableUs
Dorzolamide HydrochlorideSolution / drops20 mg/mLOphthalmicA S Medication Solutions2008-10-28Not applicableUs
Dorzolamide HydrochlorideSolution / drops20 mg/mLOphthalmicREMEDYREPACK INC.2013-11-18Not applicableUs
Dorzolamide Hydrochloride Ophthalmic Solution 2%, 10ml Ophthalmic Solution 2%, 10mlSolution22.3 mg/mLOphthalmicAlvogen Inc.2013-12-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Act DorzotimololActavis Pharma Company
Apo-dorzo-timopApotex Inc
CosoptMerck Sharp & Dohme Corp.
Cosopt PFMerck Sharp & Dohme Corp.
Dorzolamide HCl /timolol MaleateREMEDYREPACK INC.
Dorzolamide HCl and Timolol MaleateActavis Pharma, Inc.
Dorzolamide Hydrochloride and Timolol MaleateHi Tech Pharmacal Co., Inc.
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic SolutionBausch & Lomb Inc
Dorzolamide Hydrochloride-timolol MaleateLannett Company, Inc.
Dorzolamide Hydrochloride-timolol Maleate Ophthalmic Solution Sterile Ophthalmic SolutionAlvogen Inc.
Jamp-dorzolamide/timololJamp Pharma Corporation
Med-dorzolamide-timololGeneric Medical Partners Inc
Mint-dorzolamide/timololMint Pharmaceuticals Inc
Mylan-dorzolamide/timololMylan Pharmaceuticals Ulc
PMS-dorzolamide-timololPharmascience Inc
Riva-dorzolamide/timololLaboratoire Riva Inc
Sandoz Dorzolamide/timololSandoz Canada Incorporated
Teva-dorzotimolTeva Canada Limited
Van-dorzolamide-timololVanc Pharmaceuticals Inc
Salts
Name/CASStructureProperties
Dorzolamide Hydrochloride
130693-82-2
Thumb
  • InChI Key: OSRUSFPMRGDLAG-QMGYSKNISA-N
  • Monoisotopic Mass: 360.0038983
  • Average Mass: 360.89
DBSALT000931
Categories
UNII9JDX055TW1
CAS number120279-96-1
WeightAverage: 324.44
Monoisotopic: 324.02721908
Chemical FormulaC10H16N2O4S3
InChI KeyIAVUPMFITXYVAF-XPUUQOCRSA-N
InChI
InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1
IUPAC Name
(2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1λ⁶-thieno[2,3-b]thiopyran-6-sulfonamide
SMILES
CCN[[email protected]]1C[[email protected]](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Structured Indications
PharmacodynamicsDorzolamide is topical CA inhibitor that is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Dorzolamide reduces IOP by approximately 17-23% in patients with elevater IOP.
Mechanism of actionDorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed.
TargetKindPharmacological actionActionsOrganismUniProt ID
Carbonic anhydrase 2Proteinyes
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinunknown
inhibitor
HumanP22748 details
Carbonic anhydrase 1Proteinunknown
inhibitor
HumanP00915 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding~33%
MetabolismNot Available
Route of eliminationDorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine.
Half life4 months
ClearanceNot Available
ToxicityDizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Dorzolamide.Experimental
AbirateroneThe metabolism of Dorzolamide can be decreased when combined with Abiraterone.Approved
AcebutololDorzolamide may increase the hypotensive activities of Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dorzolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dorzolamide.Approved, Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Dorzolamide.Approved, Investigational
AliskirenDorzolamide may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Dorzolamide.Approved, Withdrawn
AmbrisentanDorzolamide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineDorzolamide may increase the hypotensive activities of Amifostine.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dorzolamide.Approved
AmiodaroneThe metabolism of Dorzolamide can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Dorzolamide.Approved
AprepitantThe serum concentration of Dorzolamide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Dorzolamide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Dorzolamide.Approved
AtomoxetineThe metabolism of Dorzolamide can be decreased when combined with Atomoxetine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dorzolamide.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Dorzolamide.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Dorzolamide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Dorzolamide.Withdrawn
BepridilDorzolamide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Dorzolamide.Approved
BethanidineBethanidine may increase the hypotensive activities of Dorzolamide.Approved
BexaroteneThe serum concentration of Dorzolamide can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostDorzolamide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Dorzolamide.Approved
BoceprevirThe metabolism of Dorzolamide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Dorzolamide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dorzolamide can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumDorzolamide may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Dorzolamide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Dorzolamide.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Brinzolamide.Approved
BupranololDorzolamide may increase the hypotensive activities of Bupranolol.Approved
CandesartanCandesartan may increase the hypotensive activities of Dorzolamide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Dorzolamide.Experimental
CapecitabineThe metabolism of Dorzolamide can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilDorzolamide may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Dorzolamide.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Dorzolamide.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Dorzolamide.Approved
CarvedilolDorzolamide may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololDorzolamide may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Dorzolamide can be increased when it is combined with Ceritinib.Approved
ChlorothiazideDorzolamide may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Dorzolamide.Approved
CholecalciferolThe metabolism of Dorzolamide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilDorzolamide may increase the hypotensive activities of Cilazapril.Approved
ClarithromycinThe metabolism of Dorzolamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dorzolamide can be decreased when combined with Clemastine.Approved
ClonidineClonidine may increase the hypotensive activities of Dorzolamide.Approved
ClotrimazoleThe metabolism of Dorzolamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Dorzolamide can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Dorzolamide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Dorzolamide can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Dorzolamide.Approved
CyclosporineThe metabolism of Dorzolamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Dorzolamide.Approved
DabrafenibThe serum concentration of Dorzolamide can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Dorzolamide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dorzolamide can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDorzolamide may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Dorzolamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dorzolamide can be decreased when combined with Delavirdine.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Dorzolamide.Investigational
DeserpidineDorzolamide may increase the hypotensive activities of Deserpidine.Approved
DexamethasoneThe serum concentration of Dorzolamide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Dorzolamide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Diclofenamide.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dorzolamide.Approved
DihydralazineDorzolamide may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dorzolamide can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Dorzolamide can be decreased when combined with Diltiazem.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Dorzolamide.Approved
DoxycyclineThe metabolism of Dorzolamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dorzolamide can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Dorzolamide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineDorzolamide may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Dorzolamide.Approved, Vet Approved
EnalaprilatDorzolamide may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Dorzolamide can be decreased when it is combined with Enzalutamide.Approved
EpoprostenolDorzolamide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanDorzolamide may increase the hypotensive activities of Eprosartan.Approved
ErythromycinThe metabolism of Dorzolamide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Dorzolamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Dorzolamide.Withdrawn
EtravirineThe serum concentration of Dorzolamide can be decreased when it is combined with Etravirine.Approved
FelodipineDorzolamide may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Dorzolamide.Approved
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Dorzolamide.Approved, Withdrawn
FloxuridineThe metabolism of Dorzolamide can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Dorzolamide can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Dorzolamide can be decreased when combined with Fluorouracil.Approved
FluvastatinThe metabolism of Dorzolamide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Dorzolamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dorzolamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dorzolamide can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Dorzolamide.Approved
FosphenytoinThe metabolism of Dorzolamide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Dorzolamide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dorzolamide can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Dorzolamide can be decreased when combined with Gemfibrozil.Approved
GuanabenzGuanabenz may increase the hypotensive activities of Dorzolamide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Dorzolamide.Approved
GuanethidineDorzolamide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineDorzolamide may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumDorzolamide may increase the hypotensive activities of Hexamethonium.Experimental
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Dorzolamide.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Dorzolamide.Approved
HydralazineDorzolamide may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideDorzolamide may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Dorzolamide.Approved
IdelalisibThe serum concentration of Dorzolamide can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Dorzolamide.Approved, Investigational
ImatinibThe metabolism of Dorzolamide can be decreased when combined with Imatinib.Approved
ImidaprilDorzolamide may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Dorzolamide.Approved
IndenololDorzolamide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Dorzolamide can be decreased when combined with Indinavir.Approved
IndoraminDorzolamide may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Dorzolamide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Dorzolamide.Withdrawn
IrbesartanThe metabolism of Dorzolamide can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Dorzolamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Dorzolamide.Approved
IsradipineThe metabolism of Dorzolamide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dorzolamide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dorzolamide can be increased when it is combined with Ivacaftor.Approved
KetanserinDorzolamide may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Dorzolamide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Dorzolamide.Approved
LacidipineDorzolamide may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Dorzolamide.Approved, Investigational
LeflunomideThe metabolism of Dorzolamide can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Dorzolamide.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Dorzolamide.Approved, Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Dorzolamide.Approved
LofexidineDorzolamide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Dorzolamide can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Dorzolamide can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Dorzolamide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Dorzolamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Dorzolamide can be decreased when it is combined with Lumacaftor.Approved
MacitentanDorzolamide may increase the hypotensive activities of Macitentan.Approved
ManidipineDorzolamide may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Dorzolamide.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Dorzolamide.Approved
MemantineDorzolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dorzolamide.Approved
MetforminThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dorzolamide.Approved
MethyldopaDorzolamide may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Dorzolamide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Dorzolamide.Approved, Investigational
MetipranololDorzolamide may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Dorzolamide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Dorzolamide.Approved, Investigational
MetyrosineDorzolamide may increase the hypotensive activities of Metyrosine.Approved
MibefradilDorzolamide may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneThe serum concentration of Dorzolamide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Dorzolamide.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Dorzolamide.Approved
MitotaneThe serum concentration of Dorzolamide can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Dorzolamide.Approved
ModafinilThe serum concentration of Dorzolamide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Dorzolamide.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Dorzolamide.Approved
MoxonidineDorzolamide may increase the hypotensive activities of Moxonidine.Approved
NadololDorzolamide may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Dorzolamide can be decreased when it is combined with Nafcillin.Approved
NaftopidilDorzolamide may increase the hypotensive activities of Naftopidil.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Dorzolamide.Investigational
NebivololDorzolamide may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Dorzolamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dorzolamide can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dorzolamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dorzolamide can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Dorzolamide.Withdrawn
NicardipineThe metabolism of Dorzolamide can be decreased when combined with Nicardipine.Approved
NicorandilDorzolamide may increase the hypotensive activities of Nicorandil.Approved
NiguldipineDorzolamide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Dorzolamide can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineDorzolamide may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Dorzolamide.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Dorzolamide.Approved
NitrendipineDorzolamide may increase the hypotensive activities of Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dorzolamide.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Dorzolamide.Approved
ObinutuzumabDorzolamide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Dorzolamide.Withdrawn
OlaparibThe metabolism of Dorzolamide can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Dorzolamide.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dorzolamide.Approved
OmapatrilatDorzolamide may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Dorzolamide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Dorzolamide can be increased when it is combined with Osimertinib.Approved
OxprenololDorzolamide may increase the hypotensive activities of Oxprenolol.Approved
PalbociclibThe serum concentration of Dorzolamide can be increased when it is combined with Palbociclib.Approved
PargylinePargyline may increase the hypotensive activities of Dorzolamide.Approved
PenbutololDorzolamide may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Dorzolamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumDorzolamide may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Dorzolamide.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Dorzolamide.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Dorzolamide.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Dorzolamide.Withdrawn
PhenobarbitalThe metabolism of Dorzolamide can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineDorzolamide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Dorzolamide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Dorzolamide.Approved
PhenytoinThe metabolism of Dorzolamide can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilDorzolamide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololDorzolamide may increase the hypotensive activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Dorzolamide.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Dorzolamide.Withdrawn
PolythiazideDorzolamide may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Dorzolamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the hypotensive activities of Dorzolamide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Primidone.Approved, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Dorzolamide.Approved, Investigational
PyrimethamineThe metabolism of Dorzolamide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilDorzolamide may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineDorzolamide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineQuinine may increase the hypotensive activities of Dorzolamide.Approved
RamiprilRamipril may increase the hypotensive activities of Dorzolamide.Approved
RanolazineThe metabolism of Dorzolamide can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Dorzolamide.Approved
RemikirenRemikiren may increase the hypotensive activities of Dorzolamide.Approved
RescinnamineDorzolamide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Dorzolamide.Approved
RifabutinThe metabolism of Dorzolamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dorzolamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dorzolamide can be increased when combined with Rifapentine.Approved
RilmenidineDorzolamide may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatDorzolamide may increase the hypotensive activities of Riociguat.Approved
RitonavirThe metabolism of Dorzolamide can be decreased when combined with Ritonavir.Approved, Investigational
RituximabDorzolamide may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Dorzolamide.Withdrawn
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dorzolamide.Approved, Vet Approved
SaprisartanDorzolamide may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Dorzolamide can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Dorzolamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Dorzolamide.Approved, Investigational, Vet Approved
SelexipagDorzolamide may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Dorzolamide.Approved, Investigational
SiltuximabThe serum concentration of Dorzolamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dorzolamide can be increased when it is combined with Simeprevir.Approved
SitaxentanDorzolamide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe metabolism of Dorzolamide can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilDorzolamide may increase the hypotensive activities of Spirapril.Approved
St. John's WortThe serum concentration of Dorzolamide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dorzolamide can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Dorzolamide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Dorzolamide can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Dorzolamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the antihypertensive activities of Dorzolamide.Approved, Investigational
TelaprevirThe metabolism of Dorzolamide can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Dorzolamide can be decreased when combined with Telithromycin.Approved
TelmisartanDorzolamide may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilDorzolamide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinDorzolamide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TiboloneDorzolamide may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe metabolism of Dorzolamide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Dorzolamide can be decreased when combined with Ticlopidine.Approved
TicrynafenDorzolamide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Dorzolamide.Approved
TocilizumabThe serum concentration of Dorzolamide can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Dorzolamide.Approved, Vet Approved
TolbutamideThe metabolism of Dorzolamide can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Dorzolamide.Approved
TorasemideTorasemide may increase the hypotensive activities of Dorzolamide.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Dorzolamide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Dorzolamide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Dorzolamide.Approved
TravoprostTravoprost may increase the hypotensive activities of Dorzolamide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Dorzolamide.Approved, Investigational
TrichlormethiazideDorzolamide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinDorzolamide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanDorzolamide may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe metabolism of Dorzolamide can be decreased when combined with Trimethoprim.Approved, Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Dorzolamide.Approved, Investigational
UnoprostoneDorzolamide may increase the hypotensive activities of Unoprostone.Approved
Valproic AcidThe metabolism of Dorzolamide can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Dorzolamide can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Dorzolamide.Approved
VenlafaxineThe metabolism of Dorzolamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Dorzolamide can be decreased when combined with Verapamil.Approved
VinpocetineDorzolamide may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Dorzolamide can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineDorzolamide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Dorzolamide.Approved, Vet Approved
ZafirlukastThe metabolism of Dorzolamide can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Dorzolamide can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Laszlo Kovacs, Csaba Szabo, Erika Molnarne, Adrienne Kovacsne-Mezei, Claude Singer, Judith Aronhime, “Method of making dorzolamide hydrochloride.” U.S. Patent US20060155132, issued July 13, 2006.

US20060155132
General References
  1. Plummer CE, MacKay EO, Gelatt KN: Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol. 2006 Jul-Aug;9(4):245-9. [PubMed:16771760 ]
  2. Grover S, Apushkin MA, Fishman GA: Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006 May;141(5):850-8. Epub 2006 Mar 20. [PubMed:16546110 ]
  3. Almeida GC Jr, Faria e Souza SJ: Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res. 2006 Feb;39(2):277-81. Epub 2006 Feb 2. [PubMed:16470316 ]
  4. Martens-Lobenhoffer J, Banditt P: Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197-205. [PubMed:11929320 ]
  5. Balfour JA, Wilde MI: Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997 May;10(5):384-403. [PubMed:9143858 ]
  6. Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G: Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol. 1998;11:555-74. [PubMed:9760696 ]
External Links
ATC CodesS01EC03
AHFS Codes
  • 52:10.00
PDB Entries
FDA labelDownload (569 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.6697
Caco-2 permeable-0.6627
P-glycoprotein substrateSubstrate0.5389
P-glycoprotein inhibitor INon-inhibitor0.8855
P-glycoprotein inhibitor IINon-inhibitor0.8398
Renal organic cation transporterNon-inhibitor0.9011
CYP450 2C9 substrateNon-substrate0.7755
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5096
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7547
Ames testNon AMES toxic0.6397
CarcinogenicityNon-carcinogens0.6933
BiodegradationNot ready biodegradable0.9946
Rat acute toxicity2.2365 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9446
hERG inhibition (predictor II)Non-inhibitor0.8706
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon inc
  • Apotex inc
  • Bausch and lomb inc
  • Hi tech pharmacal co inc
  • Pharmaforce inc
  • Sandoz canada inc
  • Teva pharmaceuticals usa
  • Merck research laboratories div merck co inc
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic2 %
SolutionOphthalmic
Solution / dropsOphthalmic
SolutionOphthalmic2.0 %
Solution / dropsOphthalmic22.3 mg/mL
Solution / dropsOphthalmic20 mg/mL
SolutionOphthalmic22.3 mg/mL
SolutionOphthalmic20 mg
SolutionOphthalmic20 mg/mL
Prices
Unit descriptionCostUnit
Trusopt 2% Solution 10ml79.25USD bottle
Dorzolamide HCl 2% Solution 10ml Bottle69.42USD bottle
Dorzolamide hcl 2% eye drops6.86USD ml
Trusopt 2% eye drops6.73USD ml
Trusopt (Preservative-Free) 2 % Solution3.93USD ml
Trusopt 2 % Solution3.93USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1329211 No1994-05-032011-05-03Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point283-285 °CNot Available
logP-1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.699 mg/mLALOGPS
logP-0.5ALOGPS
logP-0.15ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)8.18ChemAxon
pKa (Strongest Basic)7.14ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area106.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity72.46 m3·mol-1ChemAxon
Polarizability31.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,3,5-trisubstituted thiophenes. These are organic compounds containing a thiophene that is trisubstituted at the C-2, C3- and C5-positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiophenes
Sub Class2,3,5-trisubstituted thiophenes
Direct Parent2,3,5-trisubstituted thiophenes
Alternative Parents
Substituents
  • 2,3,5-trisubstituted thiophene
  • Aralkylamine
  • Thiopyran
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfone
  • Sulfonamide
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Lachmann C, Jorg KM, Trinkmann R: [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)]. Klin Monbl Augenheilkd. 1998 Dec;213(6):326-30. [PubMed:10048009 ]
  2. Wong BK, Bruhin PJ, Barrish A, Lin JH: Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab Dispos. 1996 Jun;24(6):659-63. [PubMed:8781782 ]
  3. Berg JT, Ramanathan S, Gabrielli MG, Swenson ER: Carbonic anhydrase in mammalian vascular smooth muscle. J Histochem Cytochem. 2004 Aug;52(8):1101-6. [PubMed:15258186 ]
  4. Hasegawa T, Hara K, Hata S: Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos. 1994 May-Jun;22(3):377-82. [PubMed:8070313 ]
  5. Maren TH, Conroy CW, Wynns GC, Levy NS: Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997 Feb;13(1):23-30. [PubMed:9029437 ]
  6. Sugrue MF: Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000 Jan;19(1):87-112. [PubMed:10614682 ]
  7. Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76. [PubMed:8875343 ]
  8. Srinivas SP, Ong A, Zhai CB, Bonanno JA: Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3273-8. [PubMed:12356834 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76. [PubMed:8875343 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Hasegawa T, Hara K, Hata S: Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos. 1994 May-Jun;22(3):377-82. [PubMed:8070313 ]
  2. Maren TH, Conroy CW, Wynns GC, Levy NS: Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997 Feb;13(1):23-30. [PubMed:9029437 ]
  3. Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76. [PubMed:8875343 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11